ReviewJournal of cardiovascular and thoracic research2023
Clinical characteristics, management, and outcomes of patients with primary cardiac angiosarcoma: A systematic review.
Review in Journal of cardiovascular and thoracic research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 15 citations in OpenAlex.
- Pazopanib treatment for primary cardiovascular sarcoma: A retrospective observational study and literature review.Oncology letters · 2026Article
- Multimodality treatment and survival in primary cardiac malignancies: evidence from competing-risk and machine learning analyses.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Cytological Diagnosis of Primary Cardiac Angiosarcoma Presenting With Multiple Serous Effusions: A Case Report With Cell Block.Diagnostic cytopathology · 2026Article
- Article
- Long-Term Survival after Repeat Resection and Multimodal Therapy for Primary Cardiac Angiosarcoma: A Case Report.Surgical case reports · 2026Article
- Primary Cardiac Sarcomas: Clinical Characteristics, Management, and Outcomes at a Spanish National Reference Center.Cancers · 2025Article
- Clinical characteristics and treatment outcomes of primary cardiac sarcomas: a retrospective analysis.Cardio-oncology (London, England) · 2025Article
- The bleeding heart: A case of cardiac angiosarcoma presenting with pulmonary hemorrhage and hemoptysis.Radiology case reports · 2025Article
- Cardiac angiosarcoma in acute pericardial tamponade with hemoptysis: A case report.The Journal of international medical research · 2025Article
- Primary cardiac angiosarcoma: A clinical report of 1 case and review of the literature.Medicine · 2025Review
- Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review.Current treatment options in oncology · 2025Review
- Angiosarcoma: a 10-year retrospective study from a high-volume UK regional referral centre.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Primary Pericardial Angiosarcoma Complicated by Constrictive Pericarditis.Arquivos brasileiros de cardiologia · 2025Article
- [Incidental finding of cardiac myxoma in a patient with bradyarrhythmia].Revista medica del Instituto Mexicano del Seguro Social · 2024Article
- Cardiac angiosarcoma with metastatic to lung, brain, and bone.Radiology case reports · 2024Article
- Cardiac angiosarcoma: a case report.The Journal of international medical research · 2023Article
- Clinical characteristics, management, and outcomes of patients with primary cardiac angiosarcoma: A systematic review.Journal of cardiovascular and thoracic research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors. Previous reports have shown a poor prognosis regardless of management, and no consensus or guidelines exist. It is necessary to clarify this information since patients with PCA have a short survival. Therefore, we aimed to systematically review clinical manifestations, management, and outcomes. We systematically searched in PubMed, Scopus, Web of Science, and EMBASE. We intended to include cross-sectional studies, case-control studies, cohort studies, and case series that reported clinical characteristics, management, and outcomes of patients with PCA. As a methodological approach, we used the Joanna Briggs Institute Critical Appraisal Checklist for Case Series and the Newcastle-Ottawa Scale for cohorts. We included six studies (five case series, one cohort). The mean/median age ranged from 39 to 48.9 years. Male sex was predominant. The most frequent manifestations were dyspnea (range: 50%-80%), pericardial effusion (29% & 56%), and chest pain (10%-39%). The mean tumor size ranged from 5.8 to 7.2 cm, with the majority of these localized in the right atrium (70-100%). The most common locations of metastasis were the lung (20%-55.6%), liver (10%-22.2%), and bone (10%-20%). Resection (22.9%-94%), and chemotherapy as neoadjuvant or adjuvant (30%-100%) were the most commonly used methods of treatment. Mortality ranged from 64.7% to 100%. PCA often presents late in its course and usually results in poor prognosis. We strongly recommend performing multi-institutional prospective cohorts to better study disease course and treatments to develop consensus, algorithms, and guidelines for this type of sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.